BIOMARIN PHARMACEUTICAL INC Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Biomarin Pharmaceutical Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2010 to Q2 2024.
  • Biomarin Pharmaceutical Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $47.9M, a 4.48% decline year-over-year.
  • Biomarin Pharmaceutical Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $209M, a 2.02% increase year-over-year.
  • Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2023 was $207M, a 5.5% increase from 2022.
  • Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2022 was $196M, a 0.48% decline from 2021.
  • Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2021 was $197M, a 3.98% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $209M $47.9M -$2.25M -4.48% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $212M $58.2M +$4.55M +8.48% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-26
Q4 2023 $207M $54.9M +$8.12M +17.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $199M $48.4M -$6.28M -11.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $205M $50.2M +$3.08M +6.55% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $202M $53.7M +$5.86M +12.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-26
Q4 2022 $196M $46.7M +$2.84M +6.48% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $193M $54.7M +$5.64M +11.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $188M $47.1M -$7.77M -14.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $196M $47.8M -$1.67M -3.37% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q4 2021 $197M $43.9M -$3.7M -7.77% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $201M $49M -$1.14M -2.28% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $202M $54.8M +$9.88M +22% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $192M $49.5M +$2.51M +5.34% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q4 2020 $190M $47.6M +$9.48M +24.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $180M $50.2M +$11M +28.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $169M $45M +$5.13M +12.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $164M $47M +$4.23M +9.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $160M $38.1M +$1.54M +4.22% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 $158M $39.2M +$2.13M +5.74% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $156M $39.8M +$1.22M +3.17% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $155M $42.8M +$6.15M +16.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q4 2018 $149M $36.6M +$2.97M +8.86% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $146M $37M +$1.14M +3.18% Jul 1, 2018 Sep 30, 2018 10-Q/A 2019-11-04
Q2 2018 $145M $38.6M -$1.5M -3.73% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 $146M $36.6M +$5.93M +19.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $140M $33.6M -$4.08M -10.8% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $144M $35.9M +$3M +9.12% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-26
Q2 2017 $141M $40.1M +$6.2M +18.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 $135M $30.7M +$497K +1.65% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 $135M $37.7M +$7.1M +23.2% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $128M $32.9M +$4.14M +14.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 $123M $33.9M +$4.39M +14.9% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 $119M $30.2M +$7.49M +33% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $112M $30.6M -$2.29M -6.96% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-26
Q3 2015 $114M $28.8M +$8.75M +43.8% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $105M $29.5M +$12.3M +71.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $92.8M $22.7M +$6.39M +39.2% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 $86.4M $32.9M +$10.2M +44.9% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-27
Q3 2014 $76.2M $20M +$3.8M +23.4% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-02
Q2 2014 $72.4M $17.3M +$3.32M +23.8% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $69.1M $16.3M +$4.74M +41% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q4 2013 $64.4M $22.7M +$10.6M +88% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-29
Q3 2013 $53.8M $16.2M +$4.07M +33.5% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 $49.7M $13.9M +$1.29M +10.2% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-31
Q1 2013 $48.4M $11.6M +$431K +3.87% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-02
Q4 2012 $48M $12.1M +$848K +7.56% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 $47.1M $12.1M +$521K +4.48% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-28
Q2 2012 $46.6M $12.6M +$2.03M +19.1% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-29
Q1 2012 $44.6M $11.1M +$754K +7.26% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-29
Q4 2011 $43.8M $11.2M Oct 1, 2011 Dec 31, 2011 10-K 2014-02-26
Q3 2011 $11.6M +$1.66M +16.7% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-29
Q2 2011 $10.6M +$1.44M +15.7% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-02
Q1 2011 $10.4M Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-30
Q3 2010 $9.96M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-31
Q2 2010 $9.17M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.